Injection of 37℃ contrast agent
ProcedureNonionic contrast agent is heated to 37℃ in a incubator when injection of contrast agent
NCT Number: NCT03104569
The purpose of this study is to determine the effect of normal temperature and 37℃ non-ionic contrast agent acting on ERCP-related cholangeitis after endoscopic retrograde cholangiopancreatography (ERCP) in the treatment of hilar cholangiocarcinoma.
Trial opening soon.
Get Notified18 year–90 year
All sexes
Interventional
Not applicable
The first hospital of Lanzhou university, Lanzhou, Gansu, China
At present, the common used contrast agent in ERCP is composed of ionic and non-ionic type, and the latter's advantages lie in its slighter toxic-and-side effect and favorable security. When heated to 37℃, the 20 ℃ contrast agents would be diluted to 50% consistency, then a shorter time period of its intravascular and other intracavitary stay would add to less cell damage. And the applications of heated non-ionic contrast agents could be found in computed tomography angiography(CTA), hysterosalpingography (HSG) and cystourethrography, and consequently the patients with the intervention of heated non-ionic contrast agents felt more comfortable and fewer adverse reactions could be observed. Nevertheless, heated contrast agent was rarely reported to act in ERCP. It's theoretically possible that its heat-reduced lower mucosity could help the contrast agent itself to drainage, so that the incidence of cholangeitis could be under control.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Nonionic contrast agent is heated to 37℃ in a incubator when injection of contrast agent
Time frame: 2 weeks
Acute cholangitis is defined if patients experienced abdominal pain, high fever(over 38.5℃), or chill after procedure in 2 weeks
Time frame: During procedures
The ease of contrast agent injection has been considered by ERCP assistant, a questionnaire is required to assign by the assistant
Time frame: 4 days
9 parameter will be collected in day 2 and day 4 after procedures. Abnormal in Total bilirubin (TBIL), White Blood Count (WBC), N%,Platelet( PLT), Procalcitonin(PCT) or C-reactive protein(CRP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and Gamma - glutamyl transpeptidase (GGT) required to be documented
Time frame: intraoperative
Total time of procedure
Time frame: intraoperative
The total time of X-ray exposure
Time frame: 1 months
Post-ERCP pancreatitis is defined if patients experienced abdominal pain for more than 24h after ERCP, accompanying with amylase or lipase more than 3 times equal to the upper limit of normal value.
Contact information is provided by the study sponsor or research team.
Wenbo Meng, M.D., Ph. D.
CONTACT
Xun Li, M.D., Ph. D.
CONTACT
Hepatopancreatobiliary Surgery Institute of Gansu Province
Other
Effect of 37℃ Non-ionic Contrast Agent During ERCP Procedure in Hilar Cholangiocarcinoma: A Prospective Double-blind Multicenter Randomized Controlled Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03104582
Adenocarcinoma, Bile Duct Diseases
Lanzhou, Gansu, China
View Trial DetailsNCT07129655
Bile Duct Diseases, Biliary Atresia
Geneva, Switzerland
View Trial DetailsNCT05750966
Bile Duct Diseases, Biliary Tract Diseases
Almere Stad, Flevoland, Netherlands
View Trial DetailsNCT07640243
Bile Duct Diseases, Biliary Obstruction
Ankara, Turkey (Türkiye)
View Trial Details